Johnson & Johnson stock gains 1.79 percent as Guggenheim holds Buy rating

Published on 10/07/2026 at 17:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson posted Q2 revenue of USD 25.31 billion, up 6.6 percent year over year. Johnson & Johnson stock heads toward its October 13 results with adjusted EPS guidance of USD 11.60-11.75.

Isometric 3D illustration of a pharmaceutical campus with four color-coded sectors: a blue research lab with DNA helix, a grey manufacturing floor with conveyor belts, a teal medical devices room with surgical equipment, and a warm white consumer health s — Johnson Konzern isometrisch, US4781601046 mit Forschung Produktion Medical Devices und Consumer Health, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) was trading at USD 259.35 on the NYSE on October 7, 2026, up 1.79 percent from the prior close of USD 254.78. Investing.com reported on October 7, 2026, that Guggenheim reiterated a Buy rating and a USD 287.00 price target ahead of the company's third-quarter report.

Guggenheim holds its target

Guggenheim's USD 287.00 target is unchanged, while its third-quarter 2026 revenue estimate of USD 25.49 billion exceeds consensus of USD 25.37 billion. Its earnings-per-share estimate of USD 2.49 is below the USD 2.69 consensus, according to Investing.com.

The contrast matters because revenue momentum and earnings conversion are pointing in different directions. The upcoming release will show whether new Innovative Medicine products can offset pressure from older medicines.

Q2 revenue grew 6.6 percent

Johnson & Johnson generated USD 25.31 billion in Q2 2026 revenue, a 6.6 percent increase from the year-ago quarter. Adjusted EPS reached USD 2.90 versus consensus of USD 2.84, a USD 0.06 beat, according to MarketBeat.

Management's 2026 adjusted EPS guidance stands at USD 11.60-11.75. The revenue guidance midpoint is USD 101.1 billion and the adjusted EPS midpoint is USD 11.68, as IG reported on October 7, 2026.

October 13 is the next test

MarketBeat lists October 13, 2026, before the market opens as the date for Johnson & Johnson's Q3 2026 results. The company enters that report with a USD 625.0 billion market capitalization and a 52-week range of USD 184.66 to USD 281.07.

At USD 259.35, the stock remained USD 21.72 below its 52-week high and USD 74.69 above its 52-week low. That range puts the earnings release at the center of the valuation debate, with growth in new medicines weighed against patent-expiration risks.

Consensus points to USD 288.56

The analyst consensus tracked by IG is Strong Buy from 18 analysts, with an average 12-month target of USD 288.56. The published target range runs from USD 260.00 to USD 320.00.

For investors, the key comparison is not only the average target but the gap between revenue and adjusted EPS expectations. Johnson & Johnson stock was trading at USD 259.35 on the NYSE on October 7, 2026, while the next reported figures will determine whether the current premium is supported by operating performance.